Advanced lung cancer patients see improved Read more about this drug.
Advanced lung cancer patients see improved, progression-free survival Patients with advanced non-little cell lung tumor whose disease has progressed following chemotherapy have a higher price of tumor shrinkage and an extended interval before tumor progression when bevacizumab is added to standard second-line erlotinib therapy, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago Read more about this drug . Bevacizumab in combination with chemotherapy and erlotinib only possess each demonstrated a substantial improvement in survival when used for the treating individuals with advanced non-small cell lung cancer. Experts in this stage III, multicenter scientific trial were hopeful that the combination of both agents that focus on different pathways would show a survival benefit.
‘We look forward to advancing selected compounds into preclinical development and to sharing these outcomes with potential corporate companions.’.. Advanced Life Sciences scientific publication demonstrates triterpenoids’ potential as anticancer agents Advanced Existence Sciences Holdings, Inc. , a biopharmaceutical business involved in the discovery, commercialization and development of novel medicines in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a study paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company’s core triterpenoid system technology in the discovery and advancement of new cancer therapeutic agents.Scientists at Advanced Life Sciences have got identified a novel class of proprietary triterpenoids that cause cell death predominantly via the induction of apoptosis, which really is a highly regulated process by which excessive or harmful cells are eliminated to be able to maintain normal cell development and cells homeostasis.